Arovella Therapeutics Ltd
ASX:ALA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Arovella Therapeutics Ltd
Net Income (Common)
Arovella Therapeutics Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Net Income (Common)
-AU$7.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Net Income (Common)
-AU$30.3m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Net Income (Common)
-AU$93.8m
|
CAGR 3-Years
31%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Net Income (Common)
AU$30.4m
|
CAGR 3-Years
449%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Net Income (Common)
-AU$64.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Net Income (Common)
AU$10.4m
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
Arovella Therapeutics Ltd
Glance View
Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.
See Also
What is Arovella Therapeutics Ltd's Net Income (Common)?
Net Income (Common)
-7.5m
AUD
Based on the financial report for Jun 30, 2025, Arovella Therapeutics Ltd's Net Income (Common) amounts to -7.5m AUD.
What is Arovella Therapeutics Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
5%
Over the last year, the Net Income (Common) growth was 14%. The average annual Net Income (Common) growth rates for Arovella Therapeutics Ltd have been 4% over the past three years , 5% over the past five years .
